Carboplatin/etoposide combination chemotherapy in the treatment of poor prognosis patients with small cell lung cancer. (Record no. 7450)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01627 am a2200169 4500 |
| 001 - CONTROL NUMBER | |
| control field | 2257 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Terms of availability | 0.00 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | Lung Cancer, Volume 12, Suppl 3, Pages S77 - S83 |
| 082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | PUBLICATIONS ARCHIVE CARN |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Carney, Desmond. |
| 9 (RLIN) | 32888 |
| 245 ## - TITLE STATEMENT | |
| Title | Carboplatin/etoposide combination chemotherapy in the treatment of poor prognosis patients with small cell lung cancer. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 1995 |
| 490 ## - SERIES STATEMENT | |
| Series statement | Staff Publications |
| Volume/sequential designation | Staff Publications- Carney, Desmond |
| 500 ## - GENERAL NOTE | |
| General note | A print copy of this article is held in the Oncology Resource Centre. |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Advances in the treatment of SCLC have been slow but sure over the past decade. It is now recognized that a small subset of patients may be cured of this disease, particularly with combined modality treatment with radiation therapy and systemic chemotherapy. However, perhaps only 25 of all patients will be candidates for this intensive/combined modality approach. Therefore, there is a need to identify effective combination chemotherapy regimens that can be easily administered to the remaining 75 of poor prognosis SCLC patients. Our studies and those of others would suggest that the combination of carboplatin and oral etoposide is a highly effective regimen for the treatment of these patients with results equal to and comparable with more intensive schedules. The ease of administration of this combination with acceptable toxicity would suggest that for such a subset of patients it may be the treatment of choice against which other combination schedules should be compared. |
| 9 (RLIN) | 35086 |
| 710 ## - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | ST. LUKE'S PUBLICATION ARCHIVE |
| 9 (RLIN) | 32511 |
| Withdrawn status | Lost status | Damaged status | Not for loan | Home library | Current library | Shelving location | Date acquired | Cost, normal purchase price | Total Checkouts | Full call number | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Withdrawn | Not Lost | Not Damaged | Available for Loan | St. Luke’s Radiation Oncology Network Dublin | St. Luke’s Radiation Oncology Network Dublin | AR | 14/05/2018 | 0.00 | PUBLICATIONS ARCHIVE CARN | 39015000019482 | 14/05/2018 | 14/05/2018 | 2 Week Loan |